Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03482557 · ClinicalTrials.gov registry record · NA

Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening

A NA study of Breast Cancer, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
NA
Development phase
132
Enrollment target
1
Study location

NCT03482557 is a NA study of Breast Cancer that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 132 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03482557, a NA study of Breast Cancer, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
NA
Development phase
132 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating whether contrast enhanced mammography can be used as an alternative to breast Magnetic Resonance Imaging (MRI) for cancer screening

Conditions Studied

Interventions

  • DEVICE MRI
  • DEVICE CESM

Study Locations (1)

Massachusetts

  • Beth Israel Deaconess - Boston

Trial Details

FieldValue
Enrollment Target 132 participants
Start Date 2018-05-17
Est. Completion 2023-08-30
Phase NA

What the Registry Record Tells You About NCT03482557

The ClinicalTrials.gov registry entry for NCT03482557 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which MRI is the first listed.

NCT03482557 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT03482557 about?

NCT03482557 is a clinical study titled "Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening". This research study is evaluating whether contrast enhanced mammography can be used as an alternative to breast Magnetic Resonance Imaging (MRI) for cancer screening

What is the current status of trial NCT03482557?

This trial is currently completed. It is a NA study. The enrollment target is 132 participants. The study started on 2018-05-17. Estimated completion is 2023-08-30.

What conditions does trial NCT03482557 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03482557?

The interventions under investigation include: MRI (DEVICE), CESM (DEVICE).

Who is sponsoring clinical trial NCT03482557?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03482557 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.